Skip to main content
Fig. 1 | Cancer Imaging

Fig. 1

From: 18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Fig. 1

Experimental protocol. 18F–FDG-PET/CT and MRI baseline scans were performed on day 0. Animals received either a BRAF and CDK4/6 inhibitor combination therapy (therapy group) or a volume-equivalent placebo (control group) administered daily over the course of 6 days. Follow-up 18F–FDG-PET/CT and MRI scans were performed on day 7. Subsequent to follow-up imaging, animals were sacrificed. The tumors were explanted to undergo the immunohistochemical analysis with regard to tumor microvascular density (CD31) and tumor cell proliferation (Ki-67)

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us